Cannabinoids and reward: Interactions with the opioid system

Critical Reviews in Neurobiology

Volumn 16, Issue 1-2, 2004, Pages 147-158

  Fattore, Liana ^a,b   Cossu, Gregorio ^b   Spano, Maria S ^b   Deiana, Serena ^b   Fadda, Paola ^b   Scherma, Maria ^b   Fratta, Walter ^a,b  

^a CNR   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Abuse; Behavior; Cannabinoids; Conditioned place preference; Drug addiction; Knockout mice; Opioids; Relapse; Reward; Self administration

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABIS; DEXANABINOL; DIAMORPHINE; DRONABINOL; MORPHINE; NALOXONE; NALTREXONE; NEUROTRANSMITTER; OPIATE RECEPTOR; RIMONABANT;

ADDICTION; DRUG WITHDRAWAL; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; REINFORCEMENT; REVIEW; REWARD; TRANSGENIC MOUSE;

ANIMALS; CANNABINOIDS; ENDORPHINS; MICE; MICE, KNOCKOUT; NARCOTICS; RECEPTOR, CANNABINOID, CB1; RECEPTORS, OPIOID; RECURRENCE; REWARD; SUBSTANCE-RELATED DISORDERS;

EID: 9744229962     PISSN: 08920915     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevNeurobiol.v16.i12.160     Document Type: Review

References (116)

1. Abel EL. Marijuana, the First Twelve Thousand Years. New York: Plenum Press, 1980.
2. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci 1990; 87:1932-1936.
3. Howlett AC, Bidaut-Russell M, Devane WA, Melvin LS, Johnson MR, Herkenham M. The cannabinoid receptor: biochemical, anatomical and behavioral characterization. Trends Neurosci 1990; 13:420-423.
4. Munro S, Thomas KL, Abu SM. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365:61-65.
5. Gérard CM, Mollereau C, Vassart G, Parmentier M. Molecular cloning of a human brain cannabinoid receptor which is also expressed in testis. Biochem J 1991; 279:129-134.
6. Mailleux P, Vanderhaeghen J-J. Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience 1992; 48:655-668.
7. Glass M, Dragunow M, Faull RLM. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997; 77:299-318.
8. Chen K, Kandel DB, Davies M. Relationship between frequency and quantity of marijuana use and last year proxy dependence among adolescent and adult in the United States. Drug Alcohol Depend 1997; 46:53-67.
9. Bourne PG. Polydrug abuse-status report on the federal effort. In: Senay E, Shorty V, Alksen H, editors. Development in the Field of Drug Abuse: National Drug Abuse Conference. Cambridge, MA: Schwenkman Publishing, 1975.
10. Rush CR, Roll JM, Higgins ST. Controlled laboratory studies on the effects of cocaine in combination with other commonly abused drugs in humans. In: Higgins ST, Katz JL, editors. Cocaine Abuse: Behavior, Pharmacology, and Clinical Applications. San Diego: Academy Press, 1998:239-263.
11. Lukas SE, Sholar M, Kouri E, Fukuzako H, Mendelson JH. Marihuana smoking increases plasma cocaine levels and subjective reports of euphoria in male volunteers. Pharmacol Biochem Behav 1994; 48:715-721.
12. Fattore L, Martellotta MC, Cossu G, Mascia MS, Fratta W. CB1 cannabinoid receptor agonist WIN 55,212-2 decreases intravenous cocaine self-administration in rats. Behav Brain Res 1999; 104:141-146.
13. Reid MJ, Bornheim LM. Cannabinoid-induced alterations in brain disposition of drugs of abuse. Bioch Pharmacol 2001; 61:1357-1367.
14. Parker LA, Gillies T. THC-induced place and taste aversions in Lewis and Sprague-Dawley rats. Behav Neurosci 1995; 109:71-78.
15. 9-tetrahydrocannabinol: comparison with cocaine, morphine and food reward. Life Sci 1995; 56:2073-2080.
16. McGregor IS, Issakidis CN, Prior G. Aversive effects of the synthetic cannabinoid CP 55,940 in rats. Pharm Biochem Behav 1996; 53:657-664.
17. Sañudo-Peña MC, Tsou K, Delay ER, Hohman AG, Force M, Walker JM. Endogenous cannabinoids as an aversive or counter-rewarding system in the rat. Neurosci Lett 1997; 223:125-128.
18. 1) receptors in the establishment of place conditioning in rats. Psychopharmacology 1998; 135:324-332.
19. 9-tetrahydrocannabinol, but not the endogenous cannabinoid receptor ligand anandamide, produces conditioned place avoidance. Life Sci 1998; 62:2431-2439.
20. Cheer JF, Kendall DA, Marsden CA. Cannabinoid receptors and reward in the rat: a conditioned place preference study. Psychopharmacology 2000; 151:25-30.
21. Valjent E, Maldonado R. A behavioral model to reveal place preference to delta 9-tetrahydrocannabinol in mice. Psychopharmacology 2000; 147:436-438.
22. Braida D, Pozzi M, Cavallini R, Sala M. Conditioned place preference induced by the cannabinoid agonist CP 55,940: interaction with the opioid system. Neuroscience 2001; 104:923-926.
23. Amit Z, Levitan DE, Brown ZW, Rogan F. Possible involvement of central factors in the mediation of conditioned taste aversion. Neuropharmacology 1977; 16:121-124.
24. Fischer GJ, Vail BJ. Preexposure to delta-9-THC blocks THC-induced conditioned taste aversion in rats. Behav Neural Biol 1980; 30:191-196.
25. Switzman L, Fishman B, Amit Z. Pre-exposure effects of morphine, diazepam and delta 9-THC on the formation of conditioned taste aversions. Psychopharmacology 1981; 74:149-157.
26. Onaivi ES, Green MR, Martin BR. Pharmacological characterization of cannabinoids in the elevated plus maze. J Pharmacol Exp Ther 1990; 253:1002-1009.
27. Guimaraes FS, de Aguiar JC, Mechoulam R, Breuer A. Anxiolytic effect of cannabidiol derivatives in the elevated plus-maze. Gen Pharmacol 1994; 25:161-164.
28. 1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport 1997; 8:491-496.
29. Giuliani D, Ferrari F, Ottani A. The cannabinoid agonist HU 210 modifies rat behavioral responses to novelty and stress. Pharmacol Res 2000; 41:47-53.
30. Rodgers RJ, Haller J, Halasz J, Mikics E. "One-trial sensitization" to the anxiolytic-like effects of cannabinoid receptor antagonist SR141716A in the mouse elevated plus-maze. Eur J Neurosci 2003; 17:1279-1286.
31. Marco EM, Perez-Alvarez L, Borcel E, Rubio M, Guaza C, Ambrosio E, et al. Involvement of 5-HT1A receptors in behavioral effects of the cannabinoid receptor agonist CP 55,940 in male rats. Behav Pharmacol 2004; 15:21-27.
32. Pradhan SN, Bhattacharyya AK, Aulakh CS, Pradhan S, Bailey PT. Cannabis and brain-stimulation reward. Adv Biosci 1978; 22-23:567-583.
33. Stark P, Dews PB. Cannabinoids. I. Behavioral effects. J Pharm Exp Ther 1980; 214:124-130.
34. 9- tetrahydrocannabinol. Psychopharmacology 1988; 96:142-144.
35. Arnold JC, Hunt GE, McGregor IS. Effects of the cannabinoid receptor agonist CP 55,940 and the cannabinoid receptor antagonist SR 141716 on intracranial self-stimulation in Lewis rats. Life Sci 2001; 70:97-108.
36. 1 receptor antagonist, decreases the sensitivity to the reinforcing effects of electrical brain stimulation in rats. Psychopharmacology 2001; 157:254-259.
37. Vlachou S, Nomikos GG, Panagis G. WIN 55,212-2 decreases the reinforcing actions of cocaine through CB1 cannabinoid receptor stimulation. Behav Brain Res 2003; 141:215-222.
38. Pickens R, Thompson T, Muchow DC. Cannabis and phencyclidine self-administered by animals. In: Goldfarb L, Hoffmeister F, editors. Psychic Dependence (Bayer-Symposium IV): Springer-Verlag, 1973.
39. Tanda G, Munzar P, Goldberg SR. Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nat Neurosci 2000; 3:1073-1074.
40. 9-tetrahydrocannabinol (THC) in rhesus monkeys. Pharmacologist 1971; 13:246-248.
41. Kuzmin A, Zvartau E, Gessa GL, Martellotta MC, Fratta W. Calcium antagonists isradipine and nimodipine suppress cocaine and morphine intravenous self-administration in drug-naive mice. Pharmacol Biochem Behav 1992; 41:497-500.
42. Martellotta MC, Kuzmin A, Zvartau E, Cossu G, Gessa GL, Fratta W. Isradipine inhibits nicotine intravenous self-administration in drug-naive mice. Pharmacol Biochem Behav 1995; 52:271-274.
43. Fattore L, Martellotta MC, Cossu G, Fratta W. Gamma-hydroxybutyric acid: an evaluation of its rewarding properties in rats and mice. Alcohol 2000; 20:247-256.
44. Fattore L, Cossu G, Martellotta MC, Deiana S, Fratta W. Baclofen antagonizes intravenous self-administration of gamma-hydroxybutyric acid in mice. Neuroreport 2001; 2:2243-2246.
45. Martellotta MC, Cossu G, Fattore L, Gessa GL, Fratta W. Self-administration of the cannabinoid receptor agonist WIN 55,212-2 in drug-naive mice. Neuroscience 1998; 85:327-330.
46. Fattore L, Cossu G, Martellotta MC, Fratta W. Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats. Psychopharmacology 2001; 156:410-416.
47. Justinova Z, Tanda G, Redhi GH, Goldberg SR. Self-administration of delta9-tetrahydrocannabinol by drug naive squirrel monkeys. Psychopharmacology 2003; 169:135-140.
48. Compton DR, Harris LS, Lichtman AH, Martin BR. Marijuana. Pharmacological Aspects of Drug Dependence. In: Schuster CR, Kuhar MJ, editors. Handbook of Experimental Pharmacology. Berlin-Heidelberg: Springer-Verlag, 1996:83-158.
49. Bloom AS, Dewey WL. A comparison of some pharmacological actions of morphine and delta9-tetrahydrocannabinol in the mouse. Psychopharmacology 1978; 57:243-248.
50. Dewey WL. Cannabinoid pharmacology. Pharmacol Rev 1986; 38:151-178.
51. Kumar AM, Haney M, Becker T, Thompson ML, Kream RM, Miczek K. Effect of early exposure to delta-9-tetrahydrocannabinol on the levels of opioid peptides, gonadotropin-releasing hormone and substance P in the adult male rat brain. Brain Res 1990; 525:78-83.
52. 9-tetrahydrocannabinol leads to changes in opioid-related behavioral patterns in rats. Brain Res 1995; 680:142-147.
53. Welch SP, Thomas C, Patrick GS. Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intratechal administration to mice. Possible mechanisms for interaction with morphine. J Pharmacol Exp Ther 1995; 272:310-321.
54. Wilson RS, May EL. Analgesic properties of the tetrahydrocannabinols, their metabolites and analogs. J Med Chem 1975; 18:700-703.
55. 9-tetrahydrocannabinol in rats. Eur J Pharmacol 1981; 70:219-224.
56. 9-tetrahydrocannabinol produces naloxone-blockable enhancement of pre-synaptic basal dopamine efflux in nucleus accumbens of conscious, freely moving rats as measured by intracerebral microdialysis. Psychopharmacology 1990; 102:156-162.
57. 9-tetrahydrocannabinol-induced analgesia in mice. Eur J Pharmacol 1996; 301:75-81.
58. Hine B, Friedman E, Torrelio M, Gershon S. Morphine-dependent rats: blockade of precipitated abstinence by tetrahydrocannabinol. Science 1975; 187:443-445.
59. Vela G, Ruiz-Gayo M, Fuentes JA. Anandamide decreases naloxone-precipitated withdrawal signs in mice chronically treated with morphine. Neuropharmacology 1995; 34:665-668.
60. 9-tetrahydrocannabinol-tolerant rats. Psychopharmacology 1977; 55:243-249.
61. 1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats. Neuroreport 1998; 9:3397-3402.
62. Hine B. Morphine and delta-9-tetrahydrocannabinol: two-way cross tolerance for antinociceptive and heart-rate responses in the rat. Psychopharmacology 1985; 87:34-38.
63. Smith FL, Welch SP, Martin BR. Interaction between delta-9- tetrahydrocannabinol and kappa opioids in mice. J Pharm Exp Ther 1994; 268:1381-1387.
64. Martin BR. Characterization of the antinociceptive activity of intravenously administered delta-9-tetrahydrocannabinol in mice. In: Harvey DJ, editor. Marijuana '84, Proceeding of the Oxford Symposium on Cannabis. Oxford, UK: IRL, 1985:685-692.
65. Melvin LS, Milne GM, Johnson MR, Subramaniam B, Wilken GH, Howlett AC. Structure-activity relationships for cannabinoid receptor binding and analgesic activity: studies of bicyclic cannabinoid analogs. Mol Pharmacol 1993; 44:1008-1015.
66. Tulunay FC, Ayhan IH, Sparber SB. The effects of morphine and delta-9-tetrahydrocannabinol on motor activity in rats. Psychopharmacology 1982, 78:358-360.
67. Thorat SN, Bhargava HN. Evidence for a bidirectional cross-tolerance between morphine and delta 9-tetrahydrocannabinol in mice. Eur J Pharmacol 1994; 260:5-13.
68. Massi P, Vaccani A, Romorini S, Parolaro D. Comparative characterization in the rat of the interaction between cannabinoids and opiates for their immunosuppressive and analgesic effects. J Neuroimmunol 2001; 117:116-124.
69. Cadoni C, Pisanu A, Solinas M, Acquas E, Di Chiara G. Behavioral sensitization after repeated exposure to Delta 9-tetrahydrocannabinol and cross-sensitization with morphine. Psychopharmacology 2001; 158:259-266.
70. Rubino T, Viganò D, Massi P, Parolaro D. The psychoactive ingredient of marijuana induces behavioral sensitization. Eur J Neurosci 2001; 14:884-886.
71. Lamarque S, Taghzouti K, Simon H. Chronic treatment with Delta(9)-tetrahydrocannabinol enhances the locomotor response to amphetamine and heroin. Implications for vulnerability to drug addiction. Neuropharmacology 2001; 41:118-129.
72. 9-tetrahydrocannabinol behavioral sensitization. Eur J Neurosci 2003; 17:325-330.
73. Gorriti MA, Rodriguez de Fonseca F, Navarro M, Palomo T. Chronic (-)-delta-9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats. Eur J Pharmacol 1999; 365:133-142.
74. Pontieri FE, Monnazzi P, Scontrini A, Buttarelli FR, Patacchioli FR. Behavioral sensitization to heroin by cannabinoid pretreatment in the rat. Eur J Pharmacol 2001; 421:R1-R3.
75. Pontieri FE, Monnazzi P, Scontrini A, Buttarelli FR, Patacchioli FR. Behavioral sensitization to WIN 55212,2 in rats pretreated with heroin. Brain Res 2001; 898:178-180.
76. Tanda G, Pontieri FE, Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common μ1 opioid receptor mechanism. Science 1997; 276:2048-2050.
77. Prescott WR, Gold LH, Martin BR. Evidence for separate neuronal mechanisms for the discriminative stimulus and catalepsy induced by delta 9-THC in the rat. Psychopharmacology 1992; 107:117-124.
78. Yamamoto T, Takada K. Role of cannabinoid receptor in the brain as relates to drug reward. Jpn J Pharmacol 2000; 84:229-236.
79. 9-THC training dose as a determinant for (R)-methanandamide generalization in rats. Psychopharmacology 1998; 140:519-522.
80. Rubio P, Rodriguez de Fonseca F, Martin-Calderon JL, Del Arco I, Bartolome S, Villanua MA, et al. Maternal exposure to low doses of delta9-tetrahydrocannabinol facilitates morphine-induced place conditioning in adult male offspring. Pharmacol Biochem Behav 1998; 61:229-238.
81. 9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect. Eur J Neurosci 2001; 13:1816-1824.
82. Mas-Nieto M, Pommier B, Tzavara ET, Caneparo A, Da Nascimento S, Le Fur G, et al. Reduction of opioid dependence by the CB(1) antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction. Br J Pharmacol 2001; 132:1809-1816.
83. Gardner EL, Lowinson JH. Marijuana's interactions with brain reward systems: update 1991. Pharmacol Biochem Behav 1991; 40:571-580.
84. Fratta W, Cossu G, Martellotta MC, Fattore L. A common neurobiological mechanism regulates cannabinoid and opioid rewarding effects in mice. Neurosci Lett 1999; 52:S10-S11.
85. Navarre M, Carrera MRA, Fratta W, Valverde O, Cossu G, Fattore L, et al. (2001) Functional interaction between opioid and cannabinoid systems in drug self-administration. J. Neurosci. 2001; 21:5344-5350.
86. Fattore L, Cossu G, Fratta W. Functional interaction between cannabinoids and opioids in animal models of drug addiction. Proceedings of the Frontiers in Addiction Research, NIDA symposium satellite at the SfN Meeting, 1-2 Nov. 2002, Orlando, FL.
87. Justinova Z, Tanda G, Munzar P, Goldberg SR. The opioid antagonist naltrexone reduces the reinforcing effects of Delta(9)-tetrahydrocannabinol in squirrel monkeys. Psychopharmacology 2004; 173:186-194.
88. Braida D, Pozzi M, Parolaro D, Sala M. Intracerebral self-administration of the cannabinoid receptor agonist CP 55,940 in the rat: interaction with the opioid system. Eur J Pharmacol 2001; 413:227-234.
89. Vela G, Martin S, Garcia-Gil L, Crespo JA, Ruiz-Gayo M, Fernandez-Ruiz J-J, et al. Maternal exposure to delta9-tetrahydrocannabinol facilitates morphine self-administration behavior and changes regional binding to central mu opioid receptors in adult offspring female rats. Brain Res 1998; 807:101-109.
90. Norwood CS, Cornish JL, Mallet PE, McGregor IS. Pre-exposure to the cannabinoid receptor agonist CP 55940 enhances morphine behavioral sensitization and alters morphine self-administration in Lewis rats. Eur J Pharmacol 2003; 465:105-114.
91. Gonzalez B, de Miguel R, Martin S, Perez-Rosado A, Romero J, Garcia-Lecumberri C, et al. Effects of perinatal exposure to delta 9-tetrahydrocannabinol on operant morphine-reinforced behavior. Pharmacol Biochem Behav 2003; 75:577-584.
92. Gonzalez S, Fernandez-Ruiz J, Di Marzo V, Hernandez M, Arevalo C, Nicanor C, et al. (2004) Behavioral and molecular changes elicited by acute administration of SR141716 to Delta(9)-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence. Drug Alcohol Depend 2004; 74:159-170.
93. Solinas M, Panlilio LV, Antoniou K, Pappas LA, Goldberg SR. The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4- dichlorophenyl)-4-methylpyrazole-3-carboxamide (SR 141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats. J Pharmacol Exp Ther 2003; 306:93-102.
94. De Vries TJ, Homberg JR, Binnekade R, Raaso H, Schoffelmeer AN. Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats. Psychopharmacology 2003; 168:164-169.
95. Beardsley PM, Dance ME, Bolster RL, Munzar P. Evaluation of the reinforcing effects of the cannabinoid CB1 receptor antagonist, SR141716, in rhesus monkeys. Eur J Pharmacol 2002; 435:209-216.
96. Rinaldi-Carmona M, Pialot F, Congy C, Redon E, Barth F, Bachy A, et al. Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain. Life Sci 1996; 58:1239-1247.
97. Reisine T, Brownstein MJ. Opioid and cannabinoid receptors. Curr Opin Neurobiol 1994; 4:406-412.
98. Howlett AC. Cannabinoid compound and signal transduction mechanisms. In: Pertwee RG, editor. Cannabinoid Receptor-Molecular Biology and Pharmacology. London: Academic Press, 1995.
99. 1 receptor knockout mice. Science 1999; 283:401-404.
100. 1 receptors. Eur J Neurosci 2000; 12:533-539.
101. 1 receptor knockout mice. Eur J Pharmacol 1999; 383:R1-R2.
102. Fattore L, Cossu G, Mascia MS, Obinu MC, Ledent C, Parmentier M, et al. Role of cannabinoid CB1 receptor in morphine rewarding effects in mice. Pharm Pharmacol Commmun 2000; 6:1-6.
103. 1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Behav Brain Res 2001; 118:61-65.
104. Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O. Cocaine, but not morphine, induces conditioned place preference and sensitization to locomotor responses in CB1 knockout mice. Eur J Neurosci 2000; 12:4038-4046.
105. Ghozland S, Matthes HW, Simonin F, Filliol D, Kieffer BL, Maldonado R. Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. J Neurosci 2002; 22:1146-1154.
106. Castane A, Robledo P, Matifas A, Kieffer BL, Maldonado R. Cannabinoid withdrawal syndrome is reduced in double mu and delta opioid receptor knockout mice. Eur J Neurosci 2003; 17:155-159.
107. Rice OV, Gordon N, Gifford AN. Conditioned place preference to morphine in cannabinoid CB1 receptor knockout mice. Brain Res 2002; 945:135-138.
108. Schenk S, Partridge B. Cocaine-seeking produced by experimenter- administered drug injections: dose-effect relationship in rats. Psychopharmacology 1999; 147:285-290.
109. De Vries TJ, Shaham Y, Homberg JR, Crombag H, Schuurman K, Dieben J, et al. A cannabinoid mechanism in relapse to cocaine seeking. Nat Med 2001; 7:1151-1154.
110. Fattore L, Spano MS, Cossu G, Deiana S, Fratta W. Cannabinoid mechanism in reinstatement of heroin-seeking after a long period of abstinence in rats. Eur J Neurosci 2003; 17:1723-1726.
111. 1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid-seeking behavior in the rat. Br J Pharmacol 2004; in press.
112. Anggadiredja K, Nakamichi M, Hiranita T, Tanaka H, Shoyama Y, Watanabe S, et al. Endocannabinoid System Modulates Relapse to Methamphetamine Seeking: Possible Mediation by the Arachidonic Acid Cascade. Neuropsychopharmacology 2004, Apr 7 [Epub ahead of print].
113. French ED, Dillon K, Wu X. Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. NeuroReport 1997; 8:649-652.
114. Gessa GL, Melis M, Muntoni A, Diana M. Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors. Eur J Pharmacol 1998; 341:39-44.
115. 9-tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors. Neurosci Lett 1997; 226:159-162.
116. Caillè S, Parsons LH. SR141716A reduces the reinforcing properties of heroin but not heroin-induced increases in the nucleus accumbens dopamine in rats. Eur J Neurosci 2003; 18:3145-3149.